An observational study in Biomarker, Progression and Osteosarcoma, sponsored by Peking University People's Hospital. Recruiting at 1 site in China. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-05-14.
Sponsored by Peking University People's Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Increasing data has indicated an association between increased soluble B7-H3 (sB7-H3) levels and unfavorable prognosis in patients with malignancies. However, the level of sB7-H3 and its clinical significance in osteosarcoma are not well known. In this present study, we investigated whether sB7-H3 levels in serum could be as a biomarker for osteosarcoma treatment.
403 studies on the registry are indexed under Disease Progression; 112 are open to participants now.
This study's planned enrollment of 200 is close to the median of 200 across 213 observational studies indexed under Disease Progression.
Browse Disease Progression studies →Peking University People's Hospital is the lead sponsor of 611 studies on the registry; 248 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Initial treated osteosarcoma patients in PKUPH and later would recieve definitive surgery in PKUPH with complete clinical materials.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before delivering neoadjuvant chemotherapy, using ELISA to test the protein expression of sB7-H3 of Peripheral Blood
Diagnostic Test: ELISA: enzyme-linked immunosorbent assay
After neoadjuvant chemotherapy and before definitive surgery, using ELISA to test the protein expression of sB7-H3 of Peripheral Blood
Diagnostic Test: ELISA: enzyme-linked immunosorbent assay
enzyme-linked immunosorbent assay
correlation of quantity of Protein B7-H3 Expression with clinical evaluation
Clinical evaluation according to RECIST 1.1
Time frame: 6 months
correlation of quantity of Protein B7-H3 Expression with histological responses
Histological responses according to Huvos Grade
Time frame: 6 months
correlation of quantity of Protein B7-H3 Expression with event-free survival
event-free survival calculated from starting systemic therapy to any tumor-related events for progression
Time frame: 2 years
correlation of quantity of Protein B7-H3 Expression with overall survival
overall survival calculated from starting systemic therapy to death
Time frame: 5 years
Plan to share: No
Started Jun 2023 (actual). Primary completion is estimated for Jul 2024, 12 months after the start.
Of 103 non-industry observational studies under Disease Progression, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 153. This study's planned 12 months is below that.
Counting every sponsor, half of 108 studies reached it within 68 months; a quarter within 35 and three quarters within 153.
Disease Progression covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University People's Hospital →